Actinogen Medical Limited · ASX:ACW
Actinogen Medical — Corporate Update (August 2015)
5 slides from Actinogen Medical's corporate update, August 2015
Slide 1: Investor Update August 2015 Issue 3
August 2015 ISSUE 3 Investor Update Baker Young initiates coverage 2 Xanamem™ trial update 3 Connecting with investors 6 Advisory Board 7 In this Issue on Actinogen with “buy” rating conference call Alzheimer’s drugs generating In the news AFR article highlights excitement among Wall St Xanamem™’s o
Slide 2: Baker Young initiates coverage; Xanamem trial update
August 2015 ISSUE 3 Baker Young initiates coverage on Actinogen with “buy” rating Xanamem™ trial update Adelaide-based Baker Young also pointed to recent As well as the potential for a significant Excellent progress has been made with regulatory consultancy, ERA Consulting, stockbroker Baker signifi
Slide 3: Xanamem – A new approach to treating Alzheimer's
Xanamem™ – Xanamem™ targets the stress hormone cortisol Actinogen Medical has focussed on a new of cortisone, and its active form cortisol, have particularly in the hippocampus and frontal A new approach approach to treating Alzheimer’s disease. been shown in human and animal models to cortex, the a
Slide 4: Connecting with investors, Advisory Board conference call, In the news
August 2015 ISSUE 3 Connecting with investors Advisory Board conference call Over the past few months, Actinogen Actinogen Medical attended the ASX In April, Actinogen held a conference Alzheimer’s and also “the thinking about AFR article highlights Medical has conducted a series of Spotlight Series
Slide 5: Actinogen Medical – Fast Facts
August 2015 ISSUE 3 Actinogen Medical Actinogen Medical – Fast Facts For further information, please contact: ASX Code: ACW Market capitalisation: Approximately $40m Dr Bill Ketelbey Chief Executive Officer Actinogen Medical Limited Top Shareholders: Ph: 02 8964 7401 Edinburgh Technology Fund Limite